![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, October 12, 2022 9:23:06 PM
I read a post on this board stated that Relief Therapeutics would be in talks of a phase 2 trial with Aviptadil (I assume inhaler version) for 2023. My question is why phase 2 instead of phase 3? To me the last trial was totally unfair by FDA. The length of the trial should have been longer (at least 7 days)! Why is the NIH so slow releasing the trial data ? Im sorry but I'm frustrated with the FDA! I'm having problems getting into clinical trials. They are wanting histological proof of sarcoidosis . My biopsies showed granuloma cells with sparse fibrosis. So it was inconclusive! I have all the symptoms of sarcoidosis including the horrible plaques! Oh well sorry to vent. ....
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM